Endo International

NASDAQ: ENDP · Real-Time Price · USD
0.37
0.00 (0.79%)
At close: Aug 15, 2022, 8:00 PM

Company Description

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally.

Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology.

The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections.

Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays.

The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation.

The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors.

Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Endo International
Endo International logo
Country IE
IPO Date Mar 3, 2014
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 3,103
CEO Blaise Coleman

Contact Details

Address:
Minerva House, Simmonscourt Road
DUBLIN,
IE
Website https://www.endo.com

Stock Details

Ticker Symbol ENDP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001593034
CUSIP Number
ISIN Number IE00BJ3V9050
Employer ID 68-0683755
SIC Code 2834

Key Executives

No executives data available.

Latest SEC Filings

Date Type Title
Feb 14, 2025 SCHEDULE 13G Filing
Sep 14, 2022 25-NSE Filing
Sep 08, 2022 SC 13G Statement of acquisition of beneficial ownership b...
Aug 29, 2022 8-K Current Report
Aug 29, 2022 SC 13G Statement of acquisition of beneficial ownership b...
Aug 19, 2022 8-K Current Report
Aug 17, 2022 4 Filing
Aug 17, 2022 8-K Current Report
Aug 09, 2022 10-Q Quarterly Report
Aug 09, 2022 8-K Current Report